🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

It was an honor to have Drew Moghanaki as our Sunnybrook Health Sciences Centre annual Veronique Benk Visiting Professor Radiation Oncology. He not only brought us some 🌞 from UCLA but wisdom on the challenges of performing randomized trials. I admire his tireless commitment to academic radiation oncology.

We are excited to see another ISRS guideline published in the Green Journal! "Stereotactic body radiotherapy for non-spine bone metastases: A meta-analysis and international stereotactic radiosurgery society (ISRS) clinical practice guidelines" Co-author Dr. Alexander Louie

PET surveillance in NSCLC after definitive therapy JTO & JTO CRR. SUPE_R trial randomized 750pts to PET/CT or CT alone. PET increased detection of recurrence, but no difference in those treated with curative intent (48%); no difference in survival (HR 0.97) jto.org/article/S1556-…

📢 🚨#lungcancer peeps. Please consider Prof Andrea Bezjak from University of Toronto for your next IASLC president! A very deserving candidate and a great representative for #radonc!!! Laura Dawson #lcsm

What about #SABR / #SBRT to the primary tumour in LA-NSCLC? This study just presented at #ESTRO25 has promising survival with little toxicity rates ➡️ improvement in PFS ➡️ trend toward better OS

Honoured to host the great Robert Timmerman as this year’s Dr. Alan Dembo Visiting Professor Lecturer - is pulsar the next paradigm in #radonc ?

Re-irradiation is common but challenging in lung cancer. ARS just published: American Radium Society™ Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer Executive Summary. My personalized Share Link: authors.elsevier.com/c/1l3k51Hx52Ni…

We are grateful for the tremendous response to our recent manuscript and want to ensure a precise interpretation of our findings. Our research indicates that local radiation therapy in patients with pre-existing metastases may exert paradoxical effects—reducing the dissemination

Navigational bronchoscopy at least non-inferior diagnostic yield compared to transthoracic needle biopsy for lung nodules & significantly fewer complications Is robotic bronch the new standard for lung nodule biopsy? I believe it is

Our Research Day returned on May 13 with nearly 170 participants, 66 abstracts, and a full day of innovation, connection, and discovery! Congrats to all presenters and award recipients, and thanks to keynote speaker Dr. Charles Mayo and our sponsors! uoft.me/utdro-research…

Keys to maximizing academic productivity as a trainee

Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT & SBRT. Multidisciplinary care, imaging, and innovation are key. New #OpenAccess review by Andratschke et al: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… OncoAlert #RadOnc

🧵1/ Big news in unresectable stage III NSCLC. The InTRist study is the first randomized trial comparing NAC vs. neoadjuvant chemoimmunotherapy (NAC-ICI) prior to definitive chemoradiotherapy (CRT). Early results are promising. Let’s dig in. 🔍 #LungCancer #RadOnc #ASCO25

🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo) 🔷 44% on same Rx at 12 mo 🔷 36% at 24 mo Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. ascopubs.org/doi/10.1200/OA…

Our #SABRCAN25 Lung Speakers! Friday June 6 2025 Drew Moghanaki UCLA Health - Life after VALOR: How to Consider the Possibilities Alex Louie MD, PhD Radiation Oncology Sunnybrook Health Sciences Centre - Beyond Bread and Butter - Challenging Cases in Lung SABR

Our #SABRCAN25 SABR + IO Speaker! Friday June 6 2025 Dr. Suresh Senan Vrije Universiteit Amsterdam (inactief) - A New Frontier: SABR and Immunotherapy's Collaborative Potential

Our #SABRCAN25 Oligometastasis Speaker! Friday June 6 2025 Shankar Siva Peter Mac Cancer Centre - Oligometastases to and from the Lung: Entry Points to Escape Routes

🇳🇱 🇨🇦 🇦🇺 #SABRCAN25

Alex Louie MD, PhD “Beyond Bread and Butter, challenging cases in #lungcancer SABR” 🇨🇦🍁#SABR2025 #lcsm #radonc

Here in Canada, Prof. Senan reminds us of an urban myth. 🇨🇦 #SABRCAN25 ascopubs.org/doi/10.1200/JC…